down arrow

Inhibikase Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US45719W2052
USD
1.51
0.1 (7.09%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.451.56

52 Week

1.334.20
Valuation
Technical
Day's Volume

CASH

667.1 k

Shareholding (Mar 2025)

FII

0.84%

Held by 16 FIIs

DII

78.79%

Held by 10 DIIs

Promoter

15.81%

How big is Inhibikase Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Inhibikase Therapeutics, Inc. has a market capitalization of 129.35 million, with net sales of 0.00 million and a net profit of -36.55 million over the latest four quarters. The company reported shareholder's funds of 94.87 million and total assets of 98.60 million as of Dec 24.

Market Cap: As of Jun 18, Inhibikase Therapeutics, Inc. has a market capitalization of 129.35 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Inhibikase Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -36.55 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 94.87 million and total assets of 98.60 million.

Read More

What does Inhibikase Therapeutics, Inc. do?

22-Jun-2025

Inhibikase Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $14 million and a market cap of $129.35 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -43.99%.

Overview: <BR>Inhibikase Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -14 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 129.35 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.09 <BR>Return on Equity: -43.99% <BR>Price to Book: 1.51<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Inhibikase Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of August 12, 2022, Inhibikase Therapeutics, Inc. is considered overvalued and has been downgraded to "does not qualify" due to negative financial metrics, including a P/B ratio of 1.70 and poor year-to-date performance, with a decline of 48.92%.

As of 12 August 2022, the valuation grade for Inhibikase Therapeutics, Inc. moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently considered overvalued, particularly given its negative financial metrics. The P/E ratio is not applicable due to the company being loss-making, while the Price to Book Value stands at 1.70. Additionally, the EV to EBIT and EV to EBITDA ratios are both at -1.33, reflecting severe operational challenges.<BR><BR>In comparison to its peers, Inhibikase Therapeutics, Inc. has a valuation of -3.4299, while Pulmatrix, Inc. is rated risky with a valuation of -2.4446. Other peers like Lexaria Bioscience Corp. also do not qualify, with a valuation of -2.0847. The company's return performance has been poor, with a year-to-date decline of 48.92%, contrasting sharply with the S&P 500's modest gain of 2.44% over the same period. Overall, these factors suggest that Inhibikase Therapeutics is not only overvalued but also faces significant operational and financial hurdles.

Read More

Is Inhibikase Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 22, 2025, Inhibikase Therapeutics, Inc. shows a mildly bearish trend due to a bearish RSI and signals from Bollinger Bands and moving averages, despite some offsetting strength from the weekly MACD and KST, with a year-to-date return of -52.62% compared to the S&P 500's 12.22%.

As of 22 August 2025, the technical trend for Inhibikase Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a bearish RSI on the weekly timeframe and bearish signals from Bollinger Bands and daily moving averages. However, the weekly MACD and KST are mildly bullish, providing some offsetting strength. The stock has underperformed against the S&P 500 across multiple periods, with a year-to-date return of -52.62% compared to the S&P's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 124 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.09

stock-summary
Return on Equity

-53.75%

stock-summary
Price to Book

1.55

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-10 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.72%
0%
-12.72%
6 Months
-25.62%
0%
-25.62%
1 Year
-46.07%
0%
-46.07%
2 Years
63.38%
0%
63.38%
3 Years
163.02%
0%
163.02%
4 Years
-84.75%
0%
-84.75%
5 Years
0%
0%
0.0%

Inhibikase Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Inhibikase Therapeutics, Inc. technically bullish or bearish?

As of 22 August 2025, the technical trend for Inhibikase Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a bearish RSI on the weekly timeframe and bearish signals from Bollinger Bands and daily moving averages. However, the weekly MACD and KST are mildly bullish, providing some offsetting strength. The stock has underperformed against the S&P 500 across multiple periods, with a year-to-date return of -52.62% compared to the S&P's 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-32.51%
EBIT Growth (5y)
-276.33%
EBIT to Interest (avg)
-19.65
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.09
Sales to Capital Employed (avg)
0.02
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
75.38%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.70
EV to EBIT
-1.33
EV to EBITDA
-1.33
EV to Capital Employed
-7.13
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-43.99%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 2 Schemes (4.56%)

Foreign Institutions

Held by 16 Foreign Institutions (0.84%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 27.74% vs -13.22% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.20",
          "val2": "-15.80",
          "chgp": "29.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.40",
          "val2": "1.20",
          "chgp": "-66.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.90",
          "val2": "-13.70",
          "chgp": "27.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs 200.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -44.74% vs -4.97% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.30",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-28.60",
          "val2": "-19.90",
          "chgp": "-43.72%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-27.50",
          "val2": "-19.00",
          "chgp": "-44.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-77,119.80%",
          "chgp": "7,711.98%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-11.20
-15.80
29.11%
Interest
0.00
0.00
Exceptional Items
0.40
1.20
-66.67%
Consolidate Net Profit
-9.90
-13.70
27.74%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 27.74% vs -13.22% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.30
-100.00%
Operating Profit (PBDIT) excl Other Income
-28.60
-19.90
-43.72%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-27.50
-19.00
-44.74%
Operating Profit Margin (Excl OI)
0.00%
-77,119.80%
7,711.98%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs 200.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -44.74% vs -4.97% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Inhibikase Therapeutics, Inc. stock-summary
stock-summary
Inhibikase Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."